Phase 2 Autism Spectrum Disorder Trial, Recruiting NCT06629324 Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 2 Autism Spectrum Disorder Trial, Recruiting

NCT06629324
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children between 1 and 10 years old, of any gender
  • Children whose movement abilities fall within a certain range of difficulty — from needing some assistance to move around, to having very limited movement (this is measured using a standard scale called the GMFCS, levels II to V)
  • Children who have spastic cerebral palsy that was caused by a lack of oxygen to the brain

Who may not be able to join:

  • Children who have problems with blood clotting
  • Children with serious health conditions such as severe malnutrition, heart failure, lung failure, liver failure, kidney failure, or a current active infection
  • Children whose spine is in a condition that would prevent a small tube (catheter) from being safely inserted through the spinal canal (confirm with trial site)
  • Children who have cancer
  • Children who are HIV positive, or who have an active hepatitis infection
  • Children whose haemoglobin (a measure of red blood cells in the blood) is below a certain level, specifically below 110 g/L

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Liem T Nguyen, MD., PhD, Vinmec Research Insitute of Stem Cell and Gene Technology

Phone: 800-555-5555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
15 October 2026

Where this trial is recruiting

🇻🇳 Vietnam

Primary endpoints

Adverse events and Serious adverse events; Gross Motor Function Measure-88 (GMFM-88); Gross Motor Function Classification System (GMFCS); The Mini-Manual Ability Classification System (Mini-MACS) and Manual Ability Classification System (MACS); Modified Ashworth Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov